Ryan Seewald
Overview
Ryan represents a wide variety of clients in intellectual property matters, including patent, trademark, copyright, and trade secrets matters. He represents, defends, and advises clients regarding actual, potential, and threatened litigation. He has experience with a range of patent subject matter, including chemical, mechanical, biomedical, and medical device patents. Before transitioning to focus on litigation matters, Ryan worked on patent preparation and prosecution.
Career & Education
- Hamilton College, B.A., magna cum laude, chemistry, 2010
- Emory University School of Law, J.D., with honors, Emory International Law Review, Emory OUTLaw, 2018
- Colorado
- U.S. District Court for the District of Colorado
- U.S. Court of Appeals for the Tenth Circuit
Ryan's Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Firm News | 6 min read | 01.02.24
Crowell & Moring Elects Seven New Partners, Promotes Four to Senior Counsel, and 26 to Counsel
Firm News | 1 min read | 02.24.23
Crowell & Moring’s Ryan Seewald Selected For Colorado Diverse Attorney Community Circle
Insights
Ryan's Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Firm News | 6 min read | 01.02.24
Crowell & Moring Elects Seven New Partners, Promotes Four to Senior Counsel, and 26 to Counsel
Firm News | 1 min read | 02.24.23
Crowell & Moring’s Ryan Seewald Selected For Colorado Diverse Attorney Community Circle
